CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease

American Journal of Gastroenterology

Volumn 108, Issue 8, 2013, Pages 1344-1351

  Morón, Belén ^a   Verma, Anil K ^b   Das, Prasenjit ^b   Taavela, Juha ^c,d   Dafik, Laila ^e   Diraimondo, Thomas R ^f   Albertelli, Megan A ^g   Kraemer, Thomas ^h   Mäki, Markku ^c,d   Khosla, Chaitan ^e,f   Rogler, Gerhard ^a   Makharia, Govind K ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e STANFORD UNIVERSITY   (United States)

^f Stanford University   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; SIMVASTATIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DUODENUM BIOPSY; ENTEROPATHY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL MARKERS; CELIAC DISEASE; CYTOCHROME P-450 CYP3A; DIET, GLUTEN-FREE; FEASIBILITY STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INTESTINE, SMALL; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; ROC CURVE; SIMVASTATIN;

EID: 84881123345     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.151     Document Type: Article

References (35)

1. Lohi S, Mustalahti K, Kaukinen K et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26:1217-25.
2. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33.
3. Rubio-Tapia A, Murray JA. Celiac disease. Curr Opin Gastroenterol 2010;26:116-22.
4. Gibson PR, Shepherd SJ, Tye-Din JA. For celiac disease, diagnosis is not enough. Clin Gastroenterol Hepatol 2012;10:900-1.
5. Leffl er DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol 2010;105:2520-4.
6. Tursi A, Brandimarte G, Giorgetti GM. Lack of usefulness of antitransglutaminase antibodies in assessing histologic recovery aft er gluten-free diet in celiac disease. J Clin Gastroenterol 2003;37:387-91.
7. Scanlon SA, Murray JA. Update on celiac disease-etiology, diff erential diagnosis, drug targets, and management advances. Clin Exp Gastroenterol 2011;4:297-311.
8. Mukherjee R, Kelly CP, Schuppan D. Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am 2012;22:811-31.
9. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med 2011;269:604-13.
10. Lindfors K, Lahdeaho ML, Kalliokoski S et al. Future treatment strategies for celiac disease. Expert Opin Ther Targets 2012;16:665-75.
11. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: eff ect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
12. Kolars JC, Lown KS, Schmiedlin-Ren P et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
13. Lang CC, Brown RM, Kinirons MT et al. Decreased intestinal CYP3A in celiac disease: reversal aft er successful gluten-free diet: a potential source of interindividual variability in fi rst-pass drug metabolism. Clin Pharmacol Ther 1996;59:41-6.
14. Bragde H, Jansson U, Jarlsfelt I et al. Gene expression profi ling of duodenal biopsies discriminates celiac disease mucosa from normal mucosa. Pediatr Res 2011;69:530-7.
15. Granvil CP, Yu AM, Elizondo G et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 2003;31:548-58.
16. Zhou R, Wei H, Sun R et al. Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. J Immunol 2007;178:4548-56.
17. Siegel M, Strnad P, Watts RE et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 2008;3:e1861.
18. Dafi k L, Albertelli M, Stamnaes J et al. Activation and inhibition of transglutaminase 2 in mice. PLoS One 2012;7:e30642.
19. Walker MM, Murray JA. An update in the diagnosis of coeliac disease. Histopathology 2011;59:166-79.
20. Ravelli A, Villanacci V, Monfredini C et al. How patchy is patchy villous atrophy?: distribution pattern of histological lesions in the duodenum of children with celiac disease. Am J Gastroenterol 2010;105:2103-10.
21. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (' celiac sprue '). Gastroenterology 1992;102:330-54.
22. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999;11:1185-94.
23. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56:120-4.
24. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT]identifi cation of metabolizing enzymes and eff ect of the drug on hepatic P450 s. Drug Metab Dispos 1997;25:1191-9.
25. Prueksaritanont T, Qiu Y, Mu L et al. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: eff ects of gemfi brozil. Pharm Res 2005;22:1101-9.
26. Park CG, Lee H, Choi JW et al. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther 2010;48:497-503.
27. Rubio-Tapia A, Rahim MW, See JA et al. Mucosal recovery and mortality in adults with celiac disease aft er treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412-20.
28. Lee SK, Lo W, Memeo L et al. Duodenal histology in patients with celiac disease aft er treatment with a gluten-free diet. Gastrointest Endosc 2003;57:187-91.
29. Derikx JP, Vreugdenhil AC, Van den Neucker AM et al. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 2009;43:727-33.
30. Volta U, Granito A, Parisi C et al. Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. J Clin Gastroenterol 2010;44:186-90.
31. Nachman F, Sugai E, Vazquez H et al. Serological tests for celiac disease as indicators of long-term compliance with the gluten-free diet. Eur J Gastroenterol Hepatol 2011;23:473-80.
32. Vreugdenhil AC, Wolters VM, Adriaanse MP et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011;46:1435-41.
33. Liu E, Li M, Emery L et al. Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease. J Pediatr Gastroenterol Nutr 2007;45:293-300.
34. Adriaanse MP, Tack GJ, Passos VL et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther 2013;37:482-90.
35. Macdonald WC, Brandborg LL, Flick AL et al. Studies of celiac sprue. Iv. The response of the whole length of the small bowel to a gluten-free diet. Gastroenterology 1964;47:573-89.